FDA Approves MagVenture TMS Therapy As Adjunct Treatment For Obsessive Compulsive Disorder

On August 11, 2020, MagVenture, Inc. reported that the U.S. Food and Drug Administration (FDA) cleared its transcranial magnetic stimulation (TMS) therapy device for adjunct treatment of obsessive-compulsive disorder (OCD). The MagVenture TMS Therapy can be combined in outpatient treatment with existing OCD therapies, such as pharmaceutical and behavioral therapy.

MagVenture TMS Therapy® was FDA cleared for depression in 2015. It is the first company to receive FDA clearance for the 3-minute Express TMS® – the shortest TMS treatment currently available. For the new OCD indication, MagVenture TMS Therapy targets networks in the brain that are known to . . .